Real-world Efficacy and Safety of Nivolumab for Advanced Non–Small-cell Lung Cancer: A Retrospective Multicenter Analysis
Keigo Kobayashi(Osaka Gakuin University), Tomoko Betsuyaku(Tokyo Medical University), Kenzo Soejima(Keio University), Makoto Nishino(Keio University), Takashi Inoue(Ome Municipal General Hospital), Hidefumi Koh(Tachikawa Hospital), Fumio Sakamaki(Keio University), Ichiro Nakachi(Saiseikai Utsunomiya hospital), Morio Nakamura(Saiseikai Central Hospital), Daisuke Arai(Keio University), Hiroyuki Yasuda(Beth Israel Deaconess Medical Center), Takayuki Abe(Keio University), Hiroki Tateno(Saitama Municipal Hospital), Ichiro Kawada(Keio University), Katsuhiko Naoki(Broad Institute), Takeshi Terashima(Keio University), Koichi Sayama(Beth Israel Deaconess Medical Center), Ryosuke Satomi(Tokyo Medical Center)
Cited by 55
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
Plasma Brain Natriuretic Peptide as a Prognostic Indicator in Patients With Primary Pulmonary Hypertension
|Circulation|2000|880
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
|The Lancet Oncology|2019|636
Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer
|Science Translational Medicine|2013|565